Here’s some Friday trivia for you…
Surely you know about Hong Kong being notoriously expensive for real estate.
But did you know that it has been deemed the least affordable housing market in the world 13th year in a row!
A few Australian cities have made the cut as well, with Sydney taking the second spot.
See pic below for more.
Have a nice weekend ahead.
Across Markets…
The Australian sharemarket snapped a six-session winning streak to close lower on Friday, after hotter-than-expected US inflation data finally doused the interest rate hopes which had been driving markets higher for much of the past week.
The S&P/ASX 200 ended 40 points, or 0.6 per cent, down to 7051. The All Ordinaries was also down 0.6 per cent. Despite the fall, the benchmark still closed 1.4 per cent up for the week.
Friday’s fall mirrored overnight action on the S&P 500, which closed down 0.6 per cent, after the latest headline US core consumer prices grew 0.4 per cent against a forecast rise of just 0.3 per cent.
The year-on-year growth rate held at 3.7 per cent, with economists forecasting a drop to 3.6 per cent.
The still-hot CPI figures renewed bets the US Federal Reserve was not done raising rates, sending bond yields up and equity markets down.
In Australia, rate-sensitive companies sold off with real estate and tech the worst performing of the 11 sectors on Friday, to both be down 1.9 per cent.
Healthcare stocks rose 0.9 per cent, buoyed by 1.9 per cent gain in CSL.
Meanwhile, China’s consumer inflation rate for September remained unchanged from a year earlier, leaving the nation teetering on the brink of disinflation. This compares to a 0.1 per cent year-on-year increase back in August.
In company news, shareholders in Australia’s biggest gold miner, Newcrest, overwhelmingly voted in favour of a $26.2 billion merger with US gold mining giant Newmont. Shares edged up 0.8 per cent to $26.00.
Source: AFR
Perth-headquartered clinical-stage biotechnology company PharmAust (ASX: PAA) has achieved a significant milestone with the final dosing of patients participating in the assessment of a treatment for the fatal motor neurone disease (MND/ALS).
The study has concluded that all patients participating in Cohort 4 of the in-depth trial have successfully completed dosing in its Phase 1 MEND study of monepantel (MPL) in patients with motor neurone disease.
PharmAust chief executive officer, Dr Michael Thurn, said data from the Phase 1 MEND study will now be used in an orphan drug designation (ODD) and to open an investigational new drug (IND) application with the United States Food and Drug Administration (FDA) to commence a Phase 2 study early next year.
“It’s an exciting milestone to reach knowing that some patients have been receiving treatment with monepantel for over a year now and patients have elected to continue treatment with monepantel under a compassionate use program,” Dr Thurn said.
Source: Small Caps
Sector: Lithium
Deal Type: Placement
Raise Amount: $1.75M
Latest Entry Price: $0.006 with a 1:2 AL8OA
Today’s Price Change: $0.014 +7.69%
Company: Terra Uranium (ASX:T92)
Sector: Uranium
Deal Type: IPO
Raise Amount: $7.5M
Latest Entry Price: $0.20
Today’s Price Change: $0.145 +7.41%
Company: Patagonia Lithium (ASX:PL3)
Sector: Lithium
Deal Type: IPO
Raise Amount: $8.6M
Latest Entry Price: $0.20
Today’s Price Change: $0.15 Unchanged
Company: Gold Mountain Limited (ASX:GMN)
Sector: Lithium
Deal Type: Placement
Raise Amount: $2.25M
Latest Entry Price: $0.0075
Today’s Price Change: $0.0055 -8.33%
Company: Unith Ltd. (ASX:UNT)
Sector: AI/ChatGPT
Deal Type: Placement
Raise Amount: $4.5M
Latest Entry Price: $0.033 with a 1:1 UNTO
Today’s Price Change: $0.023 +4.55%
Company: Volt Resources Ltd. (ASX:VRC)
Sector: Battery Metals
Deal Type: Placement
Raise Amount: $5.75M
Latest Entry Price: $0.011
Today’s Price Change: $0.008 -5.88%
Company: Castle Minerals Ltd. (ASX:CDT)
Sector: Battery Metals/Base Metals
Deal Type: Placement
Raise Amount: $1.52M
Latest Entry Price: $0.02 with a 2:3 CDTOA
Today’s Price Change: $0.01 Unchanged
Company: Avenira Ltd. (ASX:AEV)
Sector: Phosphate
Deal Type: Placement
Raise Amount: $2.1M
Latest Entry Price: $0.01 with a 1:2 AEVO
Today’s Price Change: $0.01 -9.09%
Company: Latrobe Magnesium Ltd. (ASX:LMG)
Sector: Magnesium
Deal Type: Placement
Raise Amount: $3M & $11.5M
Latest Entry Price: $0.10 with a 1:4 LMGO
Today’s Price Change: $0.047 -2.08%
Company: Askari Metals Ltd (ASX:AS2)
Sector: Mining
Deal Type: IPO
Raise Amount: $5.7M
Latest Entry Price: $0.35 with a 1:3 AS2O
Today’s Price Change: $0.19 +11.76%
Company: iCandy (ASX:ICI)
Sector: Gaming & Digital Advertising
Deal Type: Placement
Raise Amount: $1.25M
Latest Entry Price: $0.02 with a 1:1 ICIOB
Today’s Price Change: $0.036 -2.70%
Sector: Fintech
Deal Type: Placement
Raise Amount: $1.5M
Latest Entry Price: $0.015 with a 1:2 FFGOA
Today’s Price Change: $0.012 +4.35%
Company: Paradigm Biopharma (ASX:PAR)
Sector: Biopharma
Deal Type: IPO Cornerstone
Raise Amount: $1M+
Latest Entry Price: $0.35
Today’s Price Change: $0.625 +6.84%
Company: ReNu Energy Limited (ASX:RNE)
Sector: Energy
Deal Type: Placement
Raise Amount: $1.46M
Latest Entry Price: $0.06 with a 1:1 RNEO
Today’s Price Change: $0.029 +1.75%
Company: Carly Holdings Ltd (ASX:CL8)
Sector: AI and Car subscription
Deal Type: Placement
Raise Amount: $1.25M
Latest Entry Price: $0.025 with a 1:2 CL8O
Today’s Price Change: $0.017 Unchanged
Sector: CBD
Raise Amount: $5M
Latest Entry Price: $0.006 with a 3:2 AVEOA
Today’s Price Change: $0.0045 Unchanged
Sector: Medicinal Cannabis
Deal Type: Placement
Raise Amount: $6.6M
Latest Entry Price: $0.033 with 1:2 ECSO
Today’s Price Change: $0.025 +4.17%
If you would like more information on future Peak deals, please don’t hesitate to get in touch.
Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise and the sender is authorised to state them to be the views of Peak. Information provided in this email is general advise only and does take account your objectives, financial situation or needs. Before acting on any advice in this email, Peak recommends that you consider whether it is appropriate for your circumstances. If this email contains reference to any financial products, you should obtain the current Product Disclosure Statement (PDS) or other disclosure documents for the particular products and consider this information before making any decisions regarding the products. The Financial Services Guide (FSG) can be found at www.peakassetmanagement.com.au or by telephoning Peak on 1300 304 460
No responses yet